Kangmei Pharmaceutical: Net profit in the first quarter of 2025 was 189 million yuan, a 12.34% decrease year-on-year.

According to the announcement by Kanghobay, in the first quarter of 2025, the operating income reached 1.685 billion yuan, a year-on-year decrease of 7.64%; the net profit attributable to the shareholders of the listed company was 189 million yuan, a year-on-year decrease of 12.34%; the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 162 million yuan, a year-on-year decrease of 19.35%; the net cash flow generated from operating activities was 151 million yuan, a year-on-year decrease of 6.59%; the basic earnings per share was 0.075 yuan/share, a year-on-year decrease of 10.71%; the diluted earnings per share was 0.064 yuan/share, a year-on-year decrease of 23.81%; the weighted average return on net assets was 2.66%, a decrease of 0.38 percentage points.